These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 29084746

  • 21. Efficacy of Aerosolized Rifaximin versus Tobramycin for Treatment of Pseudomonas aeruginosa Pneumonia in Mice.
    Kirby BD, Al Ahmar R, Withers TR, Valentine ME, Valentovic M, Long TE, Gaskins JR, Yu HD.
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010865
    [Abstract] [Full Text] [Related]

  • 22. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Agyeman AA, López-Causapé C, Rogers KE, Lucas DD, Cortés-Lara S, Gomis-Font MA, Fraile-Ribot P, Figuerola J, Lang Y, Franklyn ERT, Lee WL, Zhou J, Zhang Y, Bulitta JB, Boyce JD, Nation RL, Oliver A, Landersdorfer CB.
    Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
    [Abstract] [Full Text] [Related]

  • 28. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
    Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ.
    J Antimicrob Chemother; 2016 Aug; 71(8):2218-29. PubMed ID: 27118778
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media.
    Thellin O, Zorzi W, Jolois O, Elmoualij B, Duysens G, Cahay B, Streel B, Charif M, Bastin R, Heinen E, Quatresooz P.
    Int J Antimicrob Agents; 2015 Jul; 46(1):33-8. PubMed ID: 25963337
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B, Szász M, Kristóf K, Pesti N, Krizsán G, Szentandrássy J, Rókusz L, Nagy K, Szabó D.
    Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
    [Abstract] [Full Text] [Related]

  • 34. Antibacterial activity of iron oxide, iron nitride, and tobramycin conjugated nanoparticles against Pseudomonas aeruginosa biofilms.
    Armijo LM, Wawrzyniec SJ, Kopciuch M, Brandt YI, Rivera AC, Withers NJ, Cook NC, Huber DL, Monson TC, Smyth HDC, Osiński M.
    J Nanobiotechnology; 2020 Feb 18; 18(1):35. PubMed ID: 32070354
    [Abstract] [Full Text] [Related]

  • 35. Effect of L-arginine on cystic fibrosis Pseudomonas aeruginosa biofilms.
    Eisha S, Morris AJ, Martin I, Yau YCW, Grasemann H, Waters V.
    Antimicrob Agents Chemother; 2024 Aug 07; 68(8):e0033624. PubMed ID: 39023260
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
    Tré-Hardy M, Nagant C, El Manssouri N, Vanderbist F, Traore H, Vaneechoutte M, Dehaye JP.
    Antimicrob Agents Chemother; 2010 Oct 07; 54(10):4409-15. PubMed ID: 20696878
    [Abstract] [Full Text] [Related]

  • 37. [Investigation of biofilm formation and relationship with genotype and antibiotic susceptibility of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis].
    Coban AY, Ciftci A, Onuk EE, Erturan Z, Tanriverdi Cayci Y, Durupinar B.
    Mikrobiyol Bul; 2009 Oct 07; 43(4):563-73. PubMed ID: 20084909
    [Abstract] [Full Text] [Related]

  • 38. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR, Bourget C, Mainville S, Lafleur L, Lagacé J, Montplaisir S.
    J Chemother; 1989 Jul 07; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract] [Full Text] [Related]

  • 39. Tobramycin-Treated Pseudomonas aeruginosa PA14 Enhances Streptococcus constellatus 7155 Biofilm Formation in a Cystic Fibrosis Model System.
    Price KE, Naimie AA, Griffin EF, Bay C, O'Toole GA.
    J Bacteriol; 2016 Jan 15; 198(2):237-47. PubMed ID: 26483523
    [Abstract] [Full Text] [Related]

  • 40. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S.
    Expert Rev Anti Infect Ther; 2015 Jul 15; 13(7):897-905. PubMed ID: 25921312
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.